BrainStorm Cell Therapeutics Inc. Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients
6/10/2013 10:27:40 AM
More...
|
BrainStorm Cell Therapeutics Inc. Submits Favorable Interim Safety Report for First Group of Patients in Its Phase IIa Dose-Escalating Trial
6/5/2013 10:23:52 AM
More...
|
BrainStorm Cell Therapeutics Inc. Receives 1.2 Million NIS Grant From Israel's Office of the Chief Scientist
6/4/2013 10:10:32 AM
More...
|
BrainStorm Cell Therapeutics Inc. Announces CEO Interview With The Wall Street Analyst
5/23/2013 11:40:20 AM
More...
|
BrainStorm Cell Therapeutics Inc. to Present at Several Scientific and Investment Conferences
4/10/2013 11:53:32 AM
More...
|
BrainStorm Cell Therapeutics Inc. Partners With Dana-Farber Cancer Institute for NurOwn™ Production in Phase II ALS Clinical Trial
4/8/2013 9:29:34 AM
More...
|
BrainStorm Cell Therapeutics Inc. Release: Results of NurOwn™ Clinical Trial Suggest Efficacy in ALS Patients
3/21/2013 9:56:41 AM
More...
|
Phase II ALS Clinical Trial With BrainStorm Cell Therapeutics Inc.'s NurOwn™ to be Expanded to a Third Premiere U.S. Clinical Site
3/18/2013 9:32:14 AM
More...
|
BrainStorm Cell Therapeutics Inc. Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual Meeting
3/13/2013 8:30:18 AM
More...
|
BrainStorm Cell Therapeutics Inc. Presents at the 11th International Conference on Alzheimer's and Parkinson's Disease
3/11/2013 9:30:57 AM
More...
|
|